Timothy B. Lowinger
2020
In 2020, Timothy B. Lowinger earned a total compensation of $1.3M as Chief Science and Technology Officer at Mersana Therapeutics, a 54% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $189,887 |
|---|---|
| Option Awards | $545,447 |
| Salary | $409,240 |
| Stock Awards | $195,069 |
| Other | $7,000 |
| Total | $1,346,643 |
Lowinger received $545.4K in option awards, accounting for 41% of the total pay in 2020.
Lowinger also received $189.9K in non-equity incentive plan, $409.2K in salary, $195.1K in stock awards and $7K in other compensation.
Rankings
In 2020, Timothy B. Lowinger's compensation ranked 7,324th out of 13,090 executives tracked by ExecPay. In other words, Lowinger earned more than 44.0% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 7,324 out of 13,090 | 44th |
Division Manufacturing | 3,067 out of 5,624 | 46th |
Major group Chemicals And Allied Products | 1,234 out of 2,257 | 45th |
Industry group Drugs | 1,067 out of 1,957 | 46th |
Industry Pharmaceutical Preparations | 798 out of 1,462 | 45th |
Source: SEC filing on April 27, 2021.
Lowinger's colleagues
We found four more compensation records of executives who worked with Timothy B. Lowinger at Mersana Therapeutics in 2020.
News
Mersana Therapeutics CEO Anna Protopapas' 2023 pay jumps 56% to $4.5M
April 26, 2024
Mersana Therapeutics CEO Anna Protopapas' 2022 pay falls 66% to $2.8M
April 28, 2023
Mersana Therapeutics CEO Anna Protopapas' 2021 pay jumps 226% to $8.3M
April 29, 2022
Mersana Therapeutics Chief Medical Officer Arvin Yang receives $4.5M in 2020
April 27, 2021
Mersana Therapeutics CEO Anna Protopapas' 2019 pay falls 33% to $1.7M
April 20, 2020
Mersana Therapeutics CEO Anna Protopapas' 2018 pay jumps 184% to $2.6M
April 23, 2019